日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients

自身抗体状态对系统性硬化症患者器官受累和死亡风险分层的影响:一项纳入1605例患者的法国多中心队列研究的经验

Didier, Kevin; Sobanski, Vincent; Robbins, Ailsa; Truchetet, Marie-Elise; Barnetche, Thomas; Contin-Bordes, Cécile; Hot, Arnaud; Fort, Romain; Guilpain, Philippe; Maria, Alexandre; Agard, Christian; Pennaforte, Jean-Loup; Viguier, Manuelle; Martin, Thierry; Jolly, Damien; Barbe, Coralie; Giusti, Delphine; Launay, David; Servettaz, Amélie

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France

使用lanadelumab进行HAE长期预防:获准在法国临时使用

Fain, Olivier; Du-Thanh, Aurelie; Gobert, Delphine; Launay, David; Inhaber, Neil; Boudjemia, Karima; Aubineau, Magali; Sobel, Alain; Boccon-Gibod, Isabelle; Weiss, Laurence; Bouillet, Laurence

Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis

(6R)-2-硝基-6-[4-(三氟甲氧基)苯氧基]-6,7-二氢-5H-咪唑并[2,1-b][1,3]噁嗪 (DNDI-8219) 的开发:内脏利什曼病的新先导化合物

Andrew M Thompson ,Patrick D O'Connor ,Andrew J Marshall ,Adrian Blaser ,Vanessa Yardley ,Louis Maes ,Suman Gupta ,Delphine Launay ,Stephanie Braillard ,Eric Chatelain ,Baojie Wan ,Scott G Franzblau ,Zhenkun Ma ,Christopher B Cooper ,William A Denny

7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis

7-取代的2-硝基-5,6-二氢咪唑并[2,1-b][1,3]噁嗪:新型抗结核药物,为内脏利什曼病提供了一种新的临床前候选药物

Andrew M Thompson ,Patrick D O'Connor ,Andrew J Marshall ,Vanessa Yardley ,Louis Maes ,Suman Gupta ,Delphine Launay ,Stephanie Braillard ,Eric Chatelain ,Scott G Franzblau ,Baojie Wan ,Yuehong Wang ,Zhenkun Ma ,Christopher B Cooper ,William A Denny